The purpose of this study is to evaluate the efficacy and safety of Polyunsaturated Fatty Acid for the prevention of Posttraumatic Stress Disorder (PTSD) in patients with accidental injuries.
Accidental injuries, mostly motor vehicle accident, in civilian population are frequent events. For instance, nearly one-third of injured patients appear to develop trauma-related psychiatric illness and the major diagnoses are post-traumatic stress disorder (PTSD) and depressive disorder. Omega-3 Polyunsaturated Fatty Acid (Omega-3 PUFA) has some evidence of efficacy of treatment in patients with anxiety and mood disorders, but no evidence of preventing anxiety and mood disorders that occur subsequent to accidental injuries. We evaluate efficacy and safety of Omega-3 PUFA for the secondary prevention of Posttraumatic Stress Disorder (PTSD) and related psychiatric illness in patients with accidental injury.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
15
A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
National Disaster Medical Center, Tachikawa, Tokyo ,Japan
Tachikawa, Tokyo, Japan
Total score of Clinician-Administrated PTSD Scale (CAPS)
Time frame: Three month
Incidence of diagnosis of PTSD (including partial PTSD)
Time frame: Three month, one month
Total score of Montgomery Asberg Depression Rating Scale (MADRAS)
Time frame: Three month, one month
Incidence of depression evaluated by Mini-International Neuropsychiatric Interview (MINI)
Time frame: Three month, one month
Autonomic response measured before, during and after script driven imagery and acoustic stimulation
Time frame: Three month
Score of Impact of Event Scale revised (IES-R)
Time frame: Three month, one month
Score of Hospital Anxiety and Depression scale (HADS)
Time frame: Three month, one month
Score of health related Quality of Life scale, SF-36
Time frame: Three month, one month
Score of Conner-Davidson Resilience Scale (CD-RISC)
Time frame: Three month, one month
Brain-derived neurotrophic factor (BDNF) in serum
Time frame: Three month, one month
Number of days of leave taken from the time of injury
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Three month
Buss-Perry Aggression Questionnaire (BAQ)
Time frame: Three month, one month, baseline
Total score of Clinician-Administrated PTSD Scale (CAPS)
Time frame: One month
DHEA: dehydroepiandrosterone
Time frame: Three month, one month
NPY: neuropeptide Y
Time frame: Three month, one month
IL-1 beta: interleukin 1 beta
Time frame: Three month, one month
IL-6: interleukin 6
Time frame: Three month, one month
TNF alpha: tumor necrosis factor alpha
Time frame: Three month, one month
D-serine
Time frame: Three month, one month
L-serine
Time frame: Three month, one month
DL-serine
Time frame: Three month, one month
Activin
Time frame: Three month, one month